Details

Autor(en) / Beteiligte

• Yamamoto, Ko
• Shiomi, Hiroki
• Morimoto, Takeshi
• Miyazawa, Akiyoshi
• Watanabe, Hiroki
• Nakamura, Sunao
• Suwa, Satoru
• Domei, Takenori
• Ono, Koh
• Sakamoto, Hiroki
• Shigetoshi, Masataka
• Taniguchi, Ryoji
• Okayama, Hideki
• Yokomatsu, Takafumi
• Muto, Masahiro
• Kawaguchi, Ren
• Kishi, Koichi
• Hadase, Mitsuyoshi
• Fujita, Tsutomu
• Nishida, Yasunori
• Nishino, Masami
• Otake, Hiromasa
• Natsuaki, Masahiro
• Watanabe, Hirotoshi
• Suematsu, Nobuhiro
• Tanabe, Kengo
• Abe, Mitsuru
• Hibi, Kiyoshi
• Kadota, Kazushige
• Ando, Kenji
• Kimura, Takeshi
• on behalf of the OPTIVUS-Complex PCI Investigators

Titel

Dual Antiplatelet Therapy Duration After Multivessel Optimal Intravascular Ultrasound-Guided Percutaneous Coronary Intervention

Ist Teil von

• Circulation Journal, 2023/10/25, Vol.87(11), pp.1661-1671

Ort / Verlag

Japan: The Japanese Circulation Society

Erscheinungsjahr

2023

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• Background: There is a scarcity of data evaluating contemporary real-world dual antiplatelet therapy (DAPT) strategies after percutaneous coronary intervention (PCI).Methods and Results: In the OPTIVUS-Complex PCI study multivessel cohort enrolling 982 patients undergoing multivessel PCI, including left anterior descending coronary artery using intravascular ultrasound (IVUS), we conducted 90-day landmark analyses to compare shorter and longer DAPT. DAPT discontinuation was defined as withdrawal of P2Y12inhibitors or aspirin for at least 2 months. The prevalence of acute coronary syndrome and high bleeding risk by the Bleeding Academic Research Consortium were 14.2% and 52.5%, respectively. The cumulative incidence of DAPT discontinuation was 22.6% at 90 days, and 68.8% at 1 year. In the 90-day landmark analyses, there were no differences in the incidences of a composite of death, myocardial infarction, stroke, or any coronary revascularization (5.9% vs. 9.2%, log-rank P=0.12; adjusted hazard ratio, 0.59; 95% confidence interval, 0.32–1.08; P=0.09) and BARC type 3 or 5 bleeding (1.4% vs. 1.9%, log-rank P=0.62) between the off- and on-DAPT groups at 90 days.Conclusions: The adoption of short DAPT duration was still low in this trial conducted after the release of the STOPDAPT-2 trial results. The 1-year incidence of cardiovascular events was not different between the shorter and longer DAPT groups, suggesting no apparent benefit of prolonged DAPT in reducing cardiovascular events even in patients who undergo multivessel PCI.